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Objective Osteonecrosis of the jaws is the adverse effect of antiresorptive and anti-
angiogenic agents, which is termed as medication-related osteonecrosis of the jaws 
(MRONJ). This complication, which is prominent and growing, is seen in the oral and 
maxillofacial region. This cross-sectional survey aimed to evaluate MRONJ awareness 
among Iraqi medical specialists.
Materials and Methods A questionnaire-based survey was performed on medical spe-
cialists practicing general surgery, urology, orthopedics, rheumatology, and oncology. The 
questionnaire consisted of four questions regarding drug prescription, patients’ prepara-
tion before drug administration, in addition to awareness and knowledge about MRONJ.
Results Among 132 specialists, 57% did not prescribe such drugs. A significant dif-
ference existed among groups regarding dental referral, and MRONJ awareness and 
knowledge. The highest rates were seen in the oncologist group.
Conclusions Improvement of MRONJ perception and knowledge among medical 
specialists, besides implementation of dental referral, are essential in the prevention, 
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Introduction
Antiresorptive and the antiangiogenic agents are prescribed 
by a wide variety of medical specialists for patients with 
bone metastasis, multiple myeloma, breast cancer, prostate 
cancer, or metabolic bone diseases like osteoporosis, osteo-
genesis imperfecta, Paget's disease of bone, primary hyper-
parathyroidism, fibrous dysplasia, and other conditions that 
exhibit bone fragility.1-3 In spite of these benefits, osteonecro-
sis of the jaw (ONJ) may be the serious side effect associated 
with these agents.
In 2012, the World Health Organization (WHO) stated that 
there were 14.1 million new cancer cases and 8.2 million can-
cer deaths in the world.4 Accordingly, the prescription rate of 
such medications increased. With the beginning of the present 
century, many cases of bisphosphonate-related osteonecrosis 
of the jaws (BRONJ) were reported by many researchers,5-9 
especially when BP was infused intravenously.10 Denosumab, 
which is another antiresorptive agent, and the antiangio-
genic agents like sunitinib were also found to cause jaw 
necrosis,11,12 so the term “BRONJ” changed to medication-re-
lated osteonecrosis of the jaws (MRONJ) by the American 
Association of Oral and Maxillofacial Surgeons.13
MRONJ is a growing problem since the number of patients 
receiving bisphosphonates is increasing. In the UK, the inci-
dence of MRONJ was 0.001%, as estimated in 2012, with 
number of dispensed prescriptions increasing by 2.5% over 
7 years.14 At the same time, the American Association of Oral 
and Maxillofacial Surgeons reported higher incidence of 
0.004% in 2014.13
Although physicians prescribe these medications, they 
are not concerned in treating the side effects of the drugs, 
as patients resort to dental surgeons for treatment. That 
is why awareness of the side effects of antiresorptive and 
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antiangiogenic agents and how to limit the incidence of 
MRONJ is crucial for medical specialists seen prescribing 
these drugs. This cross-sectional study aims to appraise 
MRONJ knowledge among Iraqi medical specialists.
Material and Methods
A cross-sectional based survey was performed among a sam-
ple of Iraqi medical specialists working in four Iraqi cites. 
The respondents were specialists in general surgery, urology, 
orthopedics, rheumatology, and oncology.
Over a period of 3 months, five trained dentists admin-
istered the questionnaires to specialists who were informed 
about the study protocol; the participation was voluntary 
and anonymous.
The questionnaire was designed to obtain an overview of 
the specialists’ awareness and knowledge of MRONJ. After a 
brief description of antiresorptive and antiangiogenic agents, 
the questionnaire consisted of three questions (►Fig. 1):
1. Did you prescribe these drugs? ○Yes ○No
A. If yes, are there any procedures to follow before taking 
these drugs? Please specify.
B. If no, then why?
2. What is/are the potential side effects of these drugs?
3. Within the last 5 years, did you read a scientific paper or 
attends a scientific lecture about these agents?
Only respondents who answered “yes” for the first 
question passed to the second question of the question-
naire; also, they answer a question that shed light on how 
they prepare their patients before starting drug intake. 
The second question addressed the detailed knowl-
edge about the side effect of drugs. Respondents with 
the answer “no” were asked why they did not dispense 
these drugs. Question number three shows how special-
ists are interested in improving their information regard-
ing these agents.
As the aim of our study focused on MRONJ knowl-
edge, MRONJ-related answers were only considered. The 
questionnaires were completed and returned immedi-
ately. The data was analyzed using IBM SPSS Statistics 
for Windows (version 23, IBM Corp. Armonk, NY, USA). 
The significance of differences between the groups was 
assessed using analysis of variance (one-way ANOVA), and 
Duncan test considering probability values less than 0.05 
as significant.
Results
One hundred and seventy-four specialists were asked to par-
ticipate in the survey. Forty-two (24.1%) refused to participate 
compared with 132 (75.9%) who agreed. There were 40 urolo-
gists, 38 orthopedic surgeons, 36 general surgeons, 10 oncolo-
gists, and eight rheumatologists.
As far as the first question was concerned, 57 (43.2%) 
out of 132 respondents answered “yes.” When asked as 
to how they prepare their patients before drug intake, 
only nine (15.8%) correct answers were recorded com-
pared with 48 (84.2) wrong answers (►Table  1), with a 
significant difference recorded among groups in favor of 
the oncologists’ group (►Table 2). As many as 75 (56.8%) 
specialists responded with the answer “no,” and they pro-
vided multiple such as the following:
 • These medications related to other specialties (38, 50.7%).
 • Refer patients to oncologist (12, 16%).
 • I do not know anything about these medications (7, 9.3%).
 • I have not heard about these medications before (5, 6.7%).
 • I have little information about these medications (2, 2.7%).
 • I have never used these medications before (2, 2.7%).
 • These medications may cause BRONJ (1, 1.3%).
 • No answer given by eight respondents (10.7%).
Awareness about the side effects of antiresorptive and 
antiangiogenic agents was outlined by question 2, which 
again registered significantly more correct answers from the 
oncologists group compared with the other groups (►Table 2). 
However, all respondents recorded 15 (26.3%) correct answers 
and 42 (73.7%) wrong answers (►Table 1).
By answering the third question, 55 (41.7%) out of 
132 specialists developed their knowledge on the topic in 
recent years (►Table 1). The results were significantly differ-
ent among all groups, with the lowest rates recorded in the 
urologists’ set (►Table 2).
Fig. 1 Questionnaire used in study.
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Discussion
MRONJ is one of many prominent complications in the oral 
and maxillofacial region,13which became a common problem 
since antiresorptive and antiangiogenic agents are used in 
many medical disciplines for the treatment of a wide variety 
of cases. Due to the worldwide increase in bisphosphonate 
therapy and dependence, the incidence of MRONJ continu-
ously grew.15 It was thought that awareness of the topic is 
the key to implementing preventative measures in this group 
of patients.16 Therefore, efforts were made to increase per-
ception and awareness of MRONJ among health practitioners. 
However, few studies were performed on medical doctors’ 
awareness of MRONJ, and how well they refer their patients 
to dentists.17 Researchers found that MRONJ is a predictable 
disease,18,19 so it is widely accepted that prevention is the best 
measure of MRONJ treatment.20
The duration of drugs-dependent therapy and the route 
of their administration are important risk factors that physi-
cians should take care of to prevent ONJ. Another risk factor is 
the trauma to the jaw (dental extraction, surgery to the jaws, 
dental infection and/or abscesses, their treatment by scaling 
and endodontic therapy, and ill-fitting prosthetic devices) 
which is considered as the initial step for ONJ. Therefore, pre-
vention of MRONJ by maintaining excellent oral hygiene is 
the first step to avoid dental treatments such as extraction 
and surgery.21
This fact requires doctors to implement dental referrals 
to assess patients' oral health before beginning administra-
tion of related drugs to eliminate dental problems and the 
potential risk factors.13,22,23 The long-lasting effect of these 
drugs on bone makes the routine dental assessment every 
3 months mandatory, which is to be continued for the rest of 
the patient's life.24
This study is a complementary study to previous studies 
performed on dentists.25,26 It surveyed Iraqi general surgeons, 
urologists, orthopedic surgeons, rheumatologists, and oncol-
ogists to assess their knowledge about MRONJ in the form of 
questionnaires.
Our findings showed that about half of the respondents 
did not prescribe these drugs, and most of them were urol-
ogists and general surgeons. They believed that these drugs 
were not related to their specialties, and some of them refer 
their patients to oncologists. However, they should be aware 
of ONJ, since they may prescribe or face patients suffering 
from this complication because of treatment by others.27 
Table 1  Respondents’ answers of questions




























































































































































































Abbreviations: ANOVA, analysis of variance; GS, general surgeons; Ortho. S, orthopedic surgeons; Rheuma, rheumatologists.
*Significant (p < 0.05).
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In contrast, all oncologists and most orthopedic surgeons 
and rheumatologists prescribe these medications. Low rate/
absence of patient referrals for dental checkups before start-
ing drug administration was seen in most groups, perhaps 
due to their ignorance of MRONJ, as is evident from the 
answers of the second question or because there is not ade-
quate time for dental treatment, especially for advance can-
cer patients. Our results are consistent with another study 
in which different specialties were included.17 On the other 
hand, oncologists showed the best rate of dental referral 
(50%), but this rate is still low. Other researchers, through 
a study performed on oncologists, reported a comparable 
moderate dental consultation.28 In total, 84% of specialists 
in the current study did not consider dental referral in their 
treatment strategy. Other researchers29 also reported a high 
rate (62%) of physicians who did not request dental advice.
It is imperative for medical specialists to be able to iden-
tify the risk of these agents in terms of providing appropri-
ate advice and management for patients. Perception was 
significantly higher among oncologists. This may be due to 
their efforts to obtain more relevant information about the 
drugs that they prescribe. However, the need for knowl-
edge improvement among those who recorded lower scores 
is paramount. The results of this study showed that almost 
all orthopedic surgeons, most rheumatologists, and 30% of 
oncologists were unfamiliar with MRONJ. Therefore, perhaps 
they are not responsible for treating these cases. This study 
showed that 58% of specialists did not update their knowl-
edge about the topic since 5 years, which had an effect on 
patient’s awareness regarding MRONJ side effects, and how 
to prevent the serious harmful effects of these agents.30,31 
Moreover, deficiency in physician’s knowledge about MRONJ 
may result in failure in detecting the early stage of MRONJ, 
which may prevent the advanced destructive stages where 
the treatment becomes difficult to achieve.24
The number of screened specialists add a limitation to 
this study, which cannot certainly represent all medical 
specialists, nor can it exclude selection bias. Additional 
studies with a sufficient sample size along with studies from 
other medical societies may provide results that are more 
reliable.
Conclusions
The cooperation between the medical doctor and dentist 
is essential in the prevention, diagnosis, and treatment of 
MRONJ.22 We think that extra focus on MRONJ is essential 
for medical students and specialists in their curriculum, 
and at the same time, strengthening MRONJ awareness and 
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